Skip to main content
NCBI home page
Thorax logoLink to Thorax
editorial
. 1996 Mar;51(3):231–232. doi: 10.1136/thx.51.3.231

Chemotherapy in non-small cell lung cancer: time to re-examine our attitudes.

R L Souhami
PMCID: PMC1090630  PMID: 8779122

Full text

PDF
231

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. Br J Cancer. 1992 Jun;65(6):934–941. doi: 10.1038/bjc.1992.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Currie D. C., Miles D. W., Drake J. S., Rudd R., Spiro S. G., Earl H. M., Harper P. G., Tobias J. S., Souhami R. L. Mitomycin, ifosfamide and cisplatin in non-small-cell lung cancer. Cancer Chemother Pharmacol. 1990;25(5):380–381. doi: 10.1007/BF00686243. [DOI] [PubMed] [Google Scholar]
  3. Davis D. L., Hoel D., Fox J., Lopez A. International trends in cancer mortality in France, West Germany, Italy, Japan, England and Wales, and the USA. Lancet. 1990 Aug 25;336(8713):474–481. doi: 10.1016/0140-6736(90)92020-i. [DOI] [PubMed] [Google Scholar]
  4. Le Chevalier T., Arriagada R., Quoix E., Ruffie P., Martin M., Tarayre M., Lacombe-Terrier M. J., Douillard J. Y., Laplanche A. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991 Mar 20;83(6):417–423. doi: 10.1093/jnci/83.6.417. [DOI] [PubMed] [Google Scholar]
  5. Le Chevalier T., Brisgand D., Douillard J. Y., Pujol J. L., Alberola V., Monnier A., Riviere A., Lianes P., Chomy P., Cigolari S. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol. 1994 Feb;12(2):360–367. doi: 10.1200/JCO.1994.12.2.360. [DOI] [PubMed] [Google Scholar]
  6. Lilenbaum R. C., Green M. R. Novel chemotherapeutic agents in the treatment of non-small-cell lung cancer. J Clin Oncol. 1993 Jul;11(7):1391–1402. doi: 10.1200/JCO.1993.11.7.1391. [DOI] [PubMed] [Google Scholar]
  7. Pisters K. M., Kris M. G., Gralla R. J., Zaman M. B., Heelan R. T., Martini N. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future non-small-cell lung cancer combined modality trials. J Clin Oncol. 1993 Sep;11(9):1757–1762. doi: 10.1200/JCO.1993.11.9.1757. [DOI] [PubMed] [Google Scholar]
  8. Rowinsky E. K., Donehower R. C. Paclitaxel (taxol) N Engl J Med. 1995 Apr 13;332(15):1004–1014. doi: 10.1056/NEJM199504133321507. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES